The Effect of Insulin Degludec on Risk of Symptomatic Nocturnal Hypoglycaemia in Subjects With Type 1 Diabetes and High Risk of Nocturnal Severe Hypoglycaemia

Trial Profile

The Effect of Insulin Degludec on Risk of Symptomatic Nocturnal Hypoglycaemia in Subjects With Type 1 Diabetes and High Risk of Nocturnal Severe Hypoglycaemia

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Insulin degludec (Primary) ; Insulin aspart; Insulin glargine
  • Indications Hypoglycaemia; Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms HypoDeg
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 10 Jan 2015 New source identified and integrated (European Clinical Trials Database record: EudraCT2014-001942-24)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top